Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Hls Therapeutics Inc (HLS.TO)

Hls Therapeutics Inc (HLS.TO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 146,361
  • Shares Outstanding, K 31,274
  • Annual Sales, $ 56,619 K
  • Annual Income, $ -19,655 K
  • EBIT $ N/A
  • EBITDA $ N/A
  • 60-Month Beta 0.49
  • Price/Sales 1.92
  • Price/Cash Flow 7.71
  • Price/Book 1.71

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.05
  • Number of Estimates 2
  • High Estimate 0.01
  • Low Estimate -0.10
  • Prior Year -0.14
  • Growth Rate Est. (year over year) +64.29%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.30 +9.77%
on 01/14/26
4.98 -5.22%
on 12/31/25
-0.09 (-1.87%)
since 12/19/25
3-Month
4.30 +9.77%
on 01/14/26
5.62 -16.01%
on 10/27/25
-0.88 (-15.71%)
since 10/17/25
52-Week
3.90 +21.03%
on 03/17/25
5.77 -18.20%
on 10/01/25
+0.73 (+18.30%)
since 01/17/25

Most Recent Stories

More News
HLS Therapeutics Announces Health Canada Approval of NILEMDO® for the Reduction of LDL-Cholesterol in Canadians at Risk of Cardiovascular Disease

TORONTO , Nov. 18, 2025 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focused on addressing unmet needs in the treatment of psychiatric disorders and...

ESPR : 3.04 (-2.88%)
HLS.TO : 4.72 (+0.85%)
Esperion Partner HLS Therapeutics Announces Approval of NILEMDO® for the Reduction of LDL-Cholesterol in Canadians at Risk of Cardiovascular Disease

ANN ARBOR, Mich., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that HLS Therapeutics Inc. (TSX: HLS), the Company’s partner in Canada for the development and commercialization...

ESPR : 3.04 (-2.88%)
HLS.TO : 4.72 (+0.85%)
Stocks in play: HLS Therapeutics Inc.

Will release financial results for the three and nine months ended September 30, 2025, on Thursday, ...

HLS.TO : 4.72 (+0.85%)
HLS Therapeutics and Amarin Collaborate on Presenting REDUCE-IT® and EPA Mechanistic Data at the Canadian Cardiovascular Congress

TORONTO , Oct. 14, 2025 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focusing on addressing unmet needs in the treatment of psychiatric disorders and...

HLS.TO : 4.72 (+0.85%)
HLS Therapeutics Announces New Credit Agreement

TORONTO , Aug. 20, 2025 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focusing on addressing unmet needs in the treatment of psychiatric...

HLS.TO : 4.72 (+0.85%)
HLS Therapeutics Announces New Credit Agreement

/CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focusing on addressing unmet needs in the treatment of psychiatric...

JPM : 312.47 (+1.04%)
HLS.TO : 4.72 (+0.85%)
HLS Therapeutics Announces Q2 2025 Financial Results

TORONTO , Aug. 14, 2025 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focused on addressing unmet needs in the treatment of psychiatric disorders...

ESPR : 3.04 (-2.88%)
HLS.TO : 4.72 (+0.85%)
HLS Therapeutics Announces Q2 2025 Financial Results

/CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focused on addressing unmet needs in the treatment of psychiatric...

ESPR : 3.04 (-2.88%)
HLS.TO : 4.72 (+0.85%)
Stocks in play: HLS Therapeutics Inc.

Will release financial results for the three and six months ended June 30, on Thursday, August 14. The ...

HLS.TO : 4.72 (+0.85%)
HLS Therapeutics to Host Q2 2025 Financial Results Conference Call

TORONTO , July 31, 2025 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), announces that it will release financial results for the three and six months ended June 30,...

HLS.TO : 4.72 (+0.85%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Average short term outlook on maintaining the current direction.

See More Share

Business Summary

HLS Therapeutics Inc is a specialty pharmaceutical company. It is focused on the acquisition and commercialization of branded pharmaceutical products in the North American markets. The company products include Clozaril, Vascepa, CSAN Pronto, and others. The company earns revenue in the form of product...

See More

Key Turning Points

3rd Resistance Point 4.81
2nd Resistance Point 4.77
1st Resistance Point 4.74
Last Price 4.72
1st Support Level 4.67
2nd Support Level 4.63
3rd Support Level 4.60

See More

52-Week High 5.77
Fibonacci 61.8% 5.06
Fibonacci 50% 4.84
Last Price 4.72
Fibonacci 38.2% 4.61
52-Week Low 3.90

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar